news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

chinanews.com, beijing, september 1 (zhao fangyuan) another pharmaceutical company executive was officially announced to have been dismissed. according to the nanyue qingfeng website, on august 30, li chuyuan, former party secretary and chairman of guangzhou pharmaceutical group co., ltd., was suspected of serious violations of discipline and law and is currently under disciplinary review and supervision investigation by the guangdong provincial commission for discipline inspection and supervision.

in the past year, the anti-corruption campaign in the pharmaceutical industry has spread to the industry. according to incomplete statistics from china news service, since the national health commission and nine other departments launched a nationwide campaign to crack down on corruption in the pharmaceutical sector in the second half of 2023, more than 30 senior executives of pharmaceutical companies have been investigated.

senior executives of well-known domestic pharmaceutical companies such as guangzhou pharmaceutical group, pien tze huang, shanghai pharmaceuticals, china national biotec group, hisun pharmaceutical, sinopharm modern pharmaceuticals, and universal medical have been involved in corruption cases in the pharmaceutical field. in addition, the actual controllers or former senior executives of many listed companies such as yunnan baiyao, weining health, sailun bio, wohua pharmaceutical, dasanlin, huaxia ophthalmology, yangpu medical, ruiang gene, and laobaixing have been detained.

in this anti-corruption storm in the pharmaceutical industry, the focus of rectification is on the directors, supervisors and senior managers of enterprises, which is the a side, and the high sales expense ratio of pharmaceutical companies is the b side. judging from the punishment cases of the regulatory authorities in the past, the corruption of medical institutions is closely related to the violations of academic promotion and other links of pharmaceutical companies. sales promotion expenses have become the focus of inquiries for pharmaceutical companies during the ipo process.